The way you have done this is the first step (Neurobiomarker Test) and the second step (Disease Screening Test).
1. First Step – Neurobiomarker Test
In this we measure disease-related specific biomarkers (protein, peptide, genetic fragments, metabolites) in body fluids (CSF, blood, saliva).
This tells us if the disease is present or not, and if yes, how severe it is.
👉 This is just like taking a “diagnostic signal”.
2. Second Step – Disease Screening by Liquid Biopsy
This step is done to measure the progression and recovery of the disease.
When Synthetic Stem Cell Therapy is given to the patient, the new cells go into the body and
repair the damaged neurons
correct the abnormality of the immune system
and increase the plasticity of the neural network.
Now by doing Disease Screening every month we can see: how many cells have been repaired. How much the disease load (biomarker level) has reduced. And how many more cycles of therapy are required.
👉 From a scientific point of view, it is a “Therapy Monitoring Tool”.
3. How is it painless and without side effects?
Because it uses micro-nano technology of liquid biopsy (blood / CSF sample).
It uses a very thin micro-needle or micro-chip based detection system, which
neither damages the tissue,
nor does the patient feel pain.
4. Scientific Interpretation
If the biomarker level is decreasing every month → it means that Synthetic Stem Cell Therapy is effective.
If the biomarkers are stable or increasing → it means that
the disease is still active,
and additional therapy cycles are required.
In this way, this test helps the doctor to create a “treatment roadmap”.
—
🌿 In short
First step = Neurobiomarker Test = Diagnosis and baseline measurement
Second step = Disease Screening = Monitoring + Prognosis
Doing this every month shows how much the disease has improved,
how much is left,
and how many times Synthetic Stem Cell Therapy will have to be given.
What is Disease Screening?
Disease screening is a type of monitoring test, which aims to see
1. What stage the disease is in,
2. How much the disease has improved after treatment (such as Synthetic Stem Cell Therapy),
3. And how much further therapy is needed.
—
⚙ How is it done?
1. Taking samples
Blood (blood plasma/serum)
CSF (cerebrospinal fluid)
Sometimes saliva or urine
2. Measuring biomarkers
Example:
Amyloid-β/Tau protein in Alzheimer’s
α-synuclein in Parkinson’s
Neurofilament Light Chain (NfL) in MS/ALS
GFAP in Injury/Inflammation
Their levels are measured every month.
3. Comparative Analysis
Values before (baseline) and after (post-therapy) are compared.
% reduction = direct measure of improvement in disease.
—
🔬 Importance of Disease Screening from Scientific Point of View
1. Disease Burden Measurement
How much disease burden is left is directly known from biomarker level.
2. Therapy Response Tracking
If biomarkers decrease → it means treatment is working.
If they are stable → disease is under control, but more treatment is needed.
If they increase → disease is still active.
3. Treatment Planning
This test tells how many times the patient will have to repeat Synthetic Stem Cell Therapy.
4. Early Relapse Detection
Sometimes the disease is suppressed but it can emerge again.
Screening detects it beforehand.
—
📊 What information does the doctor get from Disease Screening?
Disease Status: Active, Improving, or Stable
Improvement Percentage: How many % neurons or tissues have been repaired
Therapy Requirement: How many times will the therapy have to be given
Patient Prognosis: How much time will it take for the disease to be completely cured
—
🌿 In simple language
Disease screening is a test that gives the doctor a “report card” that:
How much the disease has reduced,
How much is left,
And how much effort will have to be put in the next therapy cycle.